Find trials
Consejos para buscar

A Registry for Evaluating the Outcomes Associated with New Drug Treatments for Atrial Fibrillation, as Used in Broad Populations Outside of Clinical Trials

Overview

Información sobre este estudio

The purpose of this registry is to collect observational data for evaluating the outcomes related to the use of new target-specific antithrombotic agents, such as FXa (factor Xa) inhibitors and direct thrombin inhibitors, as they are used in broad patient populations following approval by clinical  research studies. The ORBIT-AF II registry will focus on patients with newly diagnosed atrial fibrillation (AF) as well as those who have been recently started on a target-specific oral anticoagulant agent.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Adult patients with initial diagnosis of Atrial Fibrillation, with electrocardiographic documentation 
  • Patients with an existing diagnosis of AF who had initiation or transition to an FXa (Factor Xa) inhibitor or a direct thrombin inhibitor within the preceding 3 months
  • Anticipated ability to adhere to local regularly scheduled follow-up visits

Exclusion Criteria:

  • Atrial flutter only
  • Anticipated life expectancy less than 6 months 
  • Short lasting AF secondary to a reversible condition (e.g. hyperthyroidism, pulmonary embolism, post-cardiothoracic surgery)
  • Participation in a randomized trial of anticoagulation for AF at the time of enrollment 
  • Was enrolled in the ORBIT-I Registry

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20209381

Mayo Clinic Footer